Recombinant human adenovirus type 5

重组人5型腺病毒

Report date: 2026/04/29 20:02:18

Base Information

Drug NameRecombinant human adenovirus type 5
Drug Alias Name安柯瑞OncorineH-101rAd5 H-101
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionTumor protein p53 stimulants
TargetsTumor protein p53
Therapy Area/IndicationsAscitesNasopharyngeal NeoplasmsColonic Neoplasms +[8
Global Approved IndicationsNasopharyngeal NeoplasmsNasopharyngitis
Approved Indications in ChinaNasopharyngeal NeoplasmsNasopharyngitis
Original Approved Country/TerritoryMainland China
Original Approved Date2006/04/21
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsAscitesNasopharyngeal NeoplasmsColonic Neoplasms +[7
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeL01XX
Related LinksN/A